Research

Full list of publications

  • 1. Richman IB, Long JB, Kunst N, Kyanko K, Xu X, Busch S, Gross CP. Trends in breast cancer costs among privately insured women, 40-64. JAMA Internal Medicine. 2021. doi:10.1001/jamainternmed.2021.4832
  • 2. Jongeneel G, Greuter MJE, Kunst N, van Erning FN, Koopman M, Medema JP, Vermeulen L, Vink GR, Punt CJA, Coupé VMH. Early cost-effectiveness analysis of risk-based selection for adjuvant treatment in stage II colon cancer: the potential of consensus molecular subtypes. Cancer Epidemiology, Biomarkers & Prevention. 2021. doi:10.1158/1055-9965.EPI-21-0078
image
  • 3. Kunst N, Long JB, Xu X, Busch SH, Kyanko KA, Lindau ST, Richman IB, Gross CP. Understanding variation in the cost of breast cancer screening among privately insured women in the US. Medical Care. 2021. doi:10.1097/MLR.0000000000001506
  • 4. Richman IB, Long JB, Hoag JR, Upneja A, Hooley R, Xu X, Kunst N, Aminawung JA, Kyanko KA, Busch SH, Gross CP. Comparative effectiveness of digital breast tomosynthesis for breast cancer screening among women 40-64 years old. JNCI: Journal of the National Cancer Institute. 2021. doi:10.1093/jnci/djab063
  • 5. Heath A, Strong M, Glynn D, Kunst N, Welton N, Goldhaber-Fiebert JD. Simulating Study Data to Support Expected Value of Sample Information Calculations: A Tutorial. Medical Decision Making. 2021. doi:10.1177/0272989X211026292
  • 6. Tuffaha H, Rothery C, Kunst N, Jackson C, Strong M, Birch S. A review of web-based tools for value of information analysis. Applied Health Economics and Health Policy. 2021. doi:10.1007/s40258-021-00662-4
  • 7. Upneja A, Long JB, Aminawung JA, Kyanko KA, Kunst N, Xu X., Busch SH, Gross CP, Richman IB. Comparative effectiveness of digital breast tomosynthesis and mammography among older women. Journal of General Internal Medicine. doi:10.1007/s11606-021-07132-6
  • 8. Kunst N, Wang SY, Hood A, Mougalian SS, DiGiovanna MP, Adelson K, Pusztai L. Cost-effectiveness of different neoadjuvant followed by adjuvant treatment strategies for women with HER2-positive breast cancer. JAMA Network Open. 2020. doi:10.1001/jamanetworkopen.2020.27074
  • 9. Kunst N, Alarid-Escudero F, Aas E, Coupe VMH, Schrag D, Kuntz KM. Estimating population-based recurrence rates of colorectal cancer over time in the US. Cancer Epidemiology, Biomarkers & Prevention. 2020. doi:10.1158/1055-9965.EPI-20-0490
  • 10. Kunst N, Gross CP. Breast Cancer Screening and Health Care Costs—Reply. JAMA Internal Medicine. 2020. doi:10.1001/jamainternmed.2020.2355
  • 11. Kim DD, Silver MC, Kunst N, Cohen JT, Ollendorf D, Neumann PJ. Perspective and costing in cost-effectiveness analysis, 1974-2018. PharmacoEconomics. 2020. doi:10.1007/s40273-020-00942-2
  • 12. Kunst N, Long JB, Xu X, Busch SH, Kyanko KA, Richman IB, Gross CP. Use and costs of breast cancer screening for women in their 40s in a privately insured US population. JAMA Internal Medicine. 2020. doi:10.1001/jamainternmed.2020.0262
  • 13. Kunst N, Wilson E, Glynn D, Alarid-Escudero F, Baio G, Brennan A, Fairley M, Goldhaber-Fiebert JD, Jackson C, Jalal H, Menzies NA, Strong M, Thom H, Heath A. Computing the expected value of sample information efficiently: Practical guidance and recommendations for four model-based methods. Value in Health. 2020. Editors’ Choice. doi:10.1016/j.jval.2020.02.010
  • 14. Heath A, Kunst N, Jackson C, Strong M, Alarid-Escudero F, Goldhaber-Fiebert JD, Baio G, Menzies NA, Jalal J. Calculating the Expected Value of Sample Information in Practice: Considerations from Three Case Studies. Medical Decision Making. 2020. doi:10.1177/0272989X20912402
  • 15. Kunst NR, Alarid-Escudero F, Paltiel AD, Wang SY. A value of information analysis of research on the 21-gene assay for breast cancer management. Value in Health. 2019. Editors’ Choice. doi:10.1016/j.jval.2019.05.004
  • 16. Kunst NR, Lindvik H, Carlsen KH, Haaland G, Jørgensen E, Carlsen KCL. Cost-effectiveness of diagnostic algorithms for peanut allergy in children. Journal of Allergy and Clinical Immunology. 2019. doi:10.1016/j.jaci.2018.10.050